086890.KQ ISU Abxis Co. Ltd
- Market cap
- KRW 140B
- P/E
- -
- P/B
- 1.18x
- ROE
- 5.0%
- Dividend yield
- -
- Fundamental score
- 1.1/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 086890.KQ undervalued?
Graham numberThe Graham number of ISU Abxis Co. Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ISU Abxis Co. Ltd fundamental analysis
5 of 22 checks passedROE 0/2
Low return on equity (5.0%), below 10%.
ROA 1/1
Return on assets (3.8%) is above the industry median (3.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-163.9%) is below the industry median (6.6%).
Revenue Growth 2/2
Revenue grew 11.2% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 0/1
EBIT is 1.9x against interest expense, below 5x.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (1.2x) is above the industry median (0.8x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
ISU Abxis Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ISU Abxis Co. Ltd
ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; and Clot…
Full company profileISU Abxis Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ISU Abxis Co. Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 19.1B | 19.5B | 16.7B | 21.0B | 25.6B | 28.0B | 41.2B | 54.3B | 60.3B | 56.7B | 48.8B |
| Gross Profit | 11.6B | 10.2B | 7.61B | 7.51B | 11.3B | 11.0B | 13.1B | 35.4B | 43.3B | 30.5B | 19.8B |
| Operating Income | -792M | -8.05B | -12.6B | -15.8B | -13.2B | -10.2B | -15.3B | 3.89B | -7.51B | 1.63B | -5.92B |
| EBITDA | - | - | - | - | - | - | 5.60B | 18.7B | 7.64B | -379M | 15.5B |
| Net Income | -2.04B | -8.73B | -13.0B | -17.8B | -19.9B | 830M | -7.25B | 3.61B | 14.7B | -10.7B | 5.94B |
| EPS | -98 | -350 | -488 | -669 | -703 | 25 | -218 | 104 | 410 | -262 | 146 |
| Balance Sheet | |||||||||||
| Total Assets | 59.8B | 77.8B | 69.8B | 92.8B | 82.7B | 151B | 137B | 207B | 160B | 159B | 154B |
| Total Liabilities | 14.3B | 15.7B | 10.1B | 37.6B | 39.2B | 79.1B | 72.9B | 130B | 59.4B | 44.4B | 35.6B |
| Shareholders' Equity | 45.6B | 62.1B | 59.7B | 55.2B | 43.6B | 72.0B | 64.4B | 77.2B | 101B | 114B | 119B |
| Cash & Short-term Investments | 14.9B | 29.8B | 13.1B | 31.5B | 17.5B | 39.6B | 56.0B | 119B | 28.7B | 22.6B | 23.0B |
| Total Debt | 8.37B | 7.65B | 1.80B | 24.5B | 25.0B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.71B | -6.89B | -13.4B | -13.1B | -8.56B | -5.84B | -402M | -2.69B | 2.54B | 11.0B | 8.16B |
| Capital Expenditure | 1.84B | 2.69B | 6.06B | 2.12B | 614M | 840M | 10.2B | 10.5B | 11.9B | 11.1B | 7.48B |
| Free Cash Flow | - | - | - | - | -14.5B | -7.60B | -10.6B | -13.1B | -9.34B | -89.7M | 685M |
| Ratios | |||||||||||
| ROE | -4.5% | -14.1% | -21.7% | -32.3% | -45.6% | 1.2% | -11.3% | 4.7% | 14.6% | -9.3% | 5.0% |
| ROA | -3.4% | -11.2% | -18.6% | -19.2% | -24.0% | 0.5% | -5.3% | 1.7% | 9.2% | -6.7% | 3.8% |
| Net Profit Margin | -10.7% | -44.9% | -77.6% | -84.8% | -77.6% | 3.0% | -17.6% | 6.6% | 24.4% | -18.8% | 12.2% |
| Debt to Equity | 0.18x | 0.12x | 0.03x | 0.44x | 0.57x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ISU Abxis Co. Ltd dividends
ISU Abxis Co. Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 902:859 on Oct 19, 2017.
Who owns ISU Abxis Co. Ltd
- Insiders 33.84%
- Institutions 0.10%
- Public & others 66.07%
- Shares outstanding 26.6M
- Free float 22.0M
ISU Abxis Co. Ltd company profile
- Company name
- ISU Abxis Co. Ltd
- Ticker
- 086890.KQ
- ISIN
- KR7086890001
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- Global R&D Center Building C, Seongnam-si, South Korea, 13488
- Phone
- 82 3 1696 4700
- Website
- abxis.com
About ISU Abxis Co. Ltd
ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; and Clotinab, an abciximab that is used as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications. It is also developing ISU104, a human antibody for the treatment of refractory cancer; ISU304, a modified recombinant factor IX protein for the treatment of Hemophilia B patients; and ISU305, an antibody biosimilar for paroxysmal nocturnal hemoglobinuria therapy. ISU Abxis Co., Ltd. is headquartered in Seongnam, South Korea.
ISU Abxis Co. Ltd management
10- Sang-Ho Park Ph.D.Chief Exec. Officer · born 1962
- Chang-Hoon ChoiExec. · born 1960
- Mr. Heung-Rok ParkExec. · born 1963
- Joon-Young ParkExec.
- Mr. Seungho KimExec. · born 1966
- Young-Soo SohnExec. · born 1953
- Mr. Sung-Ho ChoiExec.
- Jin-Chul ShinExec. · born 1967
- Hyun-Il KimExec.
- Jae-Heung LeeExec.